Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

Dun-Chang Mo¹, Jian-Feng Huang², Peng-Hui Luo², Long Chen³, Shang-Xiao Huang²

Affiliations

¹ Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China. Electronic address: modunchang2018@163.com.
² Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.
³ Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.

PMID: 36603930
DOI: 10.1016/S1470-2045(22)00703-3

Comment

Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

Dun-Chang Mo et al. Lancet Oncol. 2023 Jan.

. 2023 Jan;24(1):e7.

doi: 10.1016/S1470-2045(22)00703-3.

Authors

Dun-Chang Mo¹, Jian-Feng Huang², Peng-Hui Luo², Long Chen³, Shang-Xiao Huang²

Affiliations

¹ Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China. Electronic address: modunchang2018@163.com.
² Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.
³ Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.

PMID: 36603930
DOI: 10.1016/S1470-2045(22)00703-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply.
Long GV, Luke JJ, Fukunaga-Kalabis M, Ascierto PA. Long GV, et al. Lancet Oncol. 2023 Jan;24(1):e8. doi: 10.1016/S1470-2045(22)00753-7. Lancet Oncol. 2023. PMID: 36603931 Free PMC article. No abstract available.

Comment on

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

Affiliations

Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical